G6PD and prostate carcinoma: Pharmacological inhibition of G6PD activity using 6-aminonicotinamide (6-AN) resulted in a dose-dependent reduction in prostate cancer cell viability, which was greater when prostate cancer cells were cultured in the presence of bone marrow stromal cells, likely reflecting the elevated G6PD expression (Fig. 4, K and L, and fig.